126 related articles for article (PubMed ID: 38869493)
1. Fentanyl-Type Antagonist of the μ-Opioid Receptor: Important Role of Axial Chirality in the Active Conformation.
Arita H; Tanaka R; Kikukawa S; Tomizawa T; Sakata H; Funada M; Tomiyama K; Hashimoto M; Tasaka T; Tabata H; Nakamura K; Makino K; Oshitari T; Natsugari H; Takahashi H
J Med Chem; 2024 Jun; 67(12):10447-10463. PubMed ID: 38869493
[TBL] [Abstract][Full Text] [Related]
2. Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors.
Eshleman AJ; Nagarajan S; Wolfrum KM; Reed JF; Nilsen A; Torralva R; Janowsky A
Biochem Pharmacol; 2020 Dec; 182():114293. PubMed ID: 33091380
[TBL] [Abstract][Full Text] [Related]
3. Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.
Podolsky AT; Sandweiss A; Hu J; Bilsky EJ; Cain JP; Kumirov VK; Lee YS; Hruby VJ; Vardanyan RS; Vanderah TW
Life Sci; 2013 Dec; 93(25-26):1010-6. PubMed ID: 24084045
[TBL] [Abstract][Full Text] [Related]
4. Structure-Activity Relationship Studies of 6α- and 6β-Indolylacetamidonaltrexamine Derivatives as Bitopic Mu Opioid Receptor Modulators and Elaboration of the "Message-Address Concept" To Comprehend Their Functional Conversion.
Obeng S; Wang H; Jali A; Stevens DL; Akbarali HI; Dewey WL; Selley DE; Zhang Y
ACS Chem Neurosci; 2019 Mar; 10(3):1075-1090. PubMed ID: 30156823
[TBL] [Abstract][Full Text] [Related]
5. How μ-opioid receptor recognizes fentanyl.
Vo QN; Mahinthichaichan P; Shen J; Ellis CR
Nat Commun; 2021 Feb; 12(1):984. PubMed ID: 33579956
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor.
Sally EJ; Xu H; Dersch CM; Hsin LW; Chang LT; Prisinzano TE; Simpson DS; Giuvelis D; Rice KC; Jacobson AE; Cheng K; Bilsky EJ; Rothman RB
Synapse; 2010 Apr; 64(4):280-8. PubMed ID: 19953652
[TBL] [Abstract][Full Text] [Related]
7. Fentanyl but not Morphine Interacts with Nonopioid Recombinant Human Neurotransmitter Receptors and Transporters.
Torralva R; Eshleman AJ; Swanson TL; Schmachtenberg JL; Schutzer WE; Bloom SH; Wolfrum KM; Reed JF; Janowsky A
J Pharmacol Exp Ther; 2020 Sep; 374(3):376-391. PubMed ID: 32513839
[TBL] [Abstract][Full Text] [Related]
8. 'Carba'-carfentanil (trans isomer): a μ opioid receptor (MOR) partial agonist with a distinct binding mode.
Weltrowska G; Lemieux C; Chung NN; Guo JJ; Wilkes BC; Schiller PW
Bioorg Med Chem; 2014 Sep; 22(17):4581-6. PubMed ID: 25129170
[TBL] [Abstract][Full Text] [Related]
9. In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis.
Hassanien SH; Bassman JR; Perrien Naccarato CM; Twarozynski JJ; Traynor JR; Iula DM; Anand JP
Drug Test Anal; 2020 Aug; 12(8):1212-1221. PubMed ID: 32415719
[TBL] [Abstract][Full Text] [Related]
10. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.
Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Mosier PD; Kellogg GE; Dewey WL; Selley DE; Zhang Y
Bioorg Med Chem; 2015 Apr; 23(8):1701-15. PubMed ID: 25783191
[TBL] [Abstract][Full Text] [Related]
11. Binding preference at the μ-opioid receptor underlies distinct pharmacology of cyclopropyl versus valeryl analogs of fentanyl.
Xie B; Le Rouzic VP; Goldberg A; Tsai MM; Chen L; Zhang T; Sinha A; Pan YX; Baumann MH; Shi L
Neuropharmacology; 2023 Apr; 227():109442. PubMed ID: 36731721
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.
Vekariya RH; Lei W; Ray A; Saini SK; Zhang S; Molnar G; Barlow D; Karlage KL; Bilsky EJ; Houseknecht KL; Largent-Milnes TM; Streicher JM; Ananthan S
J Med Chem; 2020 Jul; 63(14):7663-7694. PubMed ID: 32530286
[TBL] [Abstract][Full Text] [Related]
13. Opioid Antagonists from the Orvinol Series as Potential Reversal Agents for Opioid Overdose.
Disney A; Olson KM; Shafer AM; Moore SC; Anand JP; Traynor JR; Husbands SM
ACS Chem Neurosci; 2022 Nov; 13(21):3108-3117. PubMed ID: 36223082
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
[TBL] [Abstract][Full Text] [Related]
15. Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effects.
Moynihan HA; Derrick I; Broadbear JH; Greedy BM; Aceto MD; Harris LS; Purington LC; Thomas MP; Woods JH; Traynor JR; Husbands SM; Lewis JW
J Med Chem; 2012 Nov; 55(22):9868-74. PubMed ID: 23043264
[TBL] [Abstract][Full Text] [Related]
16. Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.
Obeng S; Jali A; Zheng Y; Wang H; Schwienteck KL; Chen C; Stevens DL; Akbarali HI; Dewey WL; Banks ML; Liu-Chen LY; Selley DE; Zhang Y
ACS Chem Neurosci; 2019 May; 10(5):2518-2532. PubMed ID: 30758946
[TBL] [Abstract][Full Text] [Related]
17. 14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists.
Nieland NP; Rennison D; Broadbear JH; Purington L; Woods JH; Traynor JR; Lewis JW; Husbands SM
J Med Chem; 2009 Nov; 52(21):6926-30. PubMed ID: 19842669
[TBL] [Abstract][Full Text] [Related]
18. Role of Efficacy as a Determinant of Locomotor Activation by Mu Opioid Receptor Ligands in Female and Male Mice.
Santos EJ; Banks ML; Negus SS
J Pharmacol Exp Ther; 2022 Jul; 382(1):44-53. PubMed ID: 35489781
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites.
Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF
Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic Characterization of Substituted Nitazenes at
Kozell LB; Eshleman AJ; Wolfrum KM; Swanson TL; Bloom SH; Benware S; Schmachtenberg JL; Schutzer KA; Schutzer WE; Janowsky A; Abbas AI
J Pharmacol Exp Ther; 2024 Apr; 389(2):219-228. PubMed ID: 38453524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
